The purpose of the proposed study is to continue our evaluation of the therapy of malignant disease with radiolabeled antibodies. We will use I131-labeled anti-Thy 1.1 monoclonal antibodies to treat established AKR/J Thy 1.1+ lymphomas growing in AKR/Cu (Thy 1.2+) mice, where the target antigen is tumor specific, and in AKR/J (Thy 1.1+) mice, where the target antigen is expressed on normal T-cells in addition to tumor. Preliminary studies have shown that such treatment is effective against subcutaneous tumor in a setting where antibody is tumor specific. We now propose to examine the factors influencing the delivery of radiation to a solid tumor including the immunologic and pharmacologic characteristics of the carrier antibody molecule, as well as the distribution of the target antigen on both normal and malignant cells. The efficacy and toxicity of I131-antibody regimens delivering radiation to tumor at varying dose rates will be studied. The results of these studies should help elucidate principals governing therapy with radiolabeled antibodies and facilitate design of future clinical trials in humans.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA039675-02
Application #
3178970
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1985-09-01
Project End
1988-08-31
Budget Start
1986-09-01
Budget End
1987-08-31
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Badger, C C; Wilbur, D S; Hadley, S W et al. (1990) Biodistribution of p-iodobenzoyl (PIP) labeled antibodies in a murine lymphoma model. Int J Rad Appl Instrum B 17:381-7
Ali, S A; Warren, S D; Richter, K Y et al. (1990) Improving the tumor retention of radioiodinated antibody: aryl carbohydrate adducts. Cancer Res 50:783s-788s
Ali, S A; Eary, J F; Warren, S D et al. (1988) Synthesis and radioiodination of tyramine cellobiose for labeling monoclonal antibodies. Int J Rad Appl Instrum B 15:557-61
Rasey, J S; Spence, A M; Badger, C C et al. (1988) Specific protection of different normal tissues. Pharmacol Ther 39:33-43
Badger, C C; Anasetti, C; Davis, J et al. (1987) Treatment of malignancy with unmodified antibody. Pathol Immunopathol Res 6:419-34
Shulman, H M; Gown, A M; Nugent, D J (1987) Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 127:549-58
Badger, C C; Bernstein, I D (1986) Prospects for monoclonal antibody therapy of leukemia and lymphoma. Cancer 58:584-9